Atrial Fibrillation
Conditions
Keywords
paroxysmal atrial fibrillation, atrial fibrillation ablation, catheter ablation, persistent atrial fibrillation
Brief summary
DYNAMIC AF is an observational, prospective, multi-center, non-randomized registry designed to obtain real world clinical experience of radiofrequency (RF) ablation for the treatment of paroxysmal (PAF) and persistent (PsAF) atrial fibrillation ablation. Patient assessments will occur at pre- procedure, procedure, 12 weeks, 6 months and 1 year post ablation.
Detailed description
Dynamic AF is a prospective, observational, multi-center, non-randomized registry designed to obtain real world clinical experience associated with the use of Abbott technologies for AF ablation. Future technologies may be included as they become available in the market. The registry population will include patients with symptomatic PAF or PsAF that meet all eligibility criteria, who, in the opinion of the investigator, are candidates for AF ablation. All patients will be treated with commercially approved catheters and the ablation procedure will be conducted based on the current standard of care. Participation in the registry does not influence treatment decisions. All consecutive patients presenting at the institution considered for an RF ablation procedure for symptomatic PAF or PsAF should be screened by the investigator or designated member of the research team for study eligibility The primary purpose of this registry is to assess procedural efficiencies as well as long term procedural safety and effectiveness of RF ablation in the treatment of patients with paroxysmal or persistent atrial fibrillation. The registry will utilize real world clinical data obtained from the use of commercially available technologies under the authority of a health care practitioner within a legitimate practitioner-patient relationship. To support the objective of the registry, both patient information and procedure data will be collected. Patient-related data will be collected at a pre ablation office visit, a 12-week post ablation office visit, interim arrhythmia recurrence monitoring at 6- and 12-month post ablation and a 12-month post ablation office visit. Procedure related data collection will include procedural workflow and acute, mid and late onset procedure or device related complications.
Interventions
DEVICECatheter Ablation
Ablation RF technologies manufactured by Abbott.
Sponsors
Abbott
Heart Rhythm Clinical and Research Solutions, LLC
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with symptomatic, refractory or intolerant to at least one Class I or III AAD, paroxysmal atrial fibrillation (AF episode terminating spontaneously within 7 days) or symptomatic, refractory or intolerant to at least one Class I or III AAD, persistent AF (continuous AF sustained beyond 7-days and less than 1-year) who, in the opinion of the investigator, are candidates for ablation for AF. Refusal to take AADs for any reason is considered intolerant for the purposes of this protocol. * Plans to undergo an RF catheter ablation procedure using an ablation catheter manufactured by Abbott * De Novo ablation unless it is a repeat procedure for a subject whose index procedure is also included in the registry * 18 years of age or older * Able and willing to participate in baseline and follow up evaluations for the full length of the registry
Exclusion criteria
* Pregnant women * Individual who cannot read or write, or those who cannot legally consent for themselves * Participating in another clinical trial or has participated in a clinical trial within 30 days prior to screening that may interfere with this registry. * Long-standing persistent AF (continuous AF sustained \>=1 year) * Previous left atrial surgery for atrial fibrillation * Having a repeat ablation, unless the subject's index ablation procedure is also included in the registry * In the opinion of the investigator, any known contraindication to an ablation procedure or to any device or drug required for use during an ablation procedure as assessed by the investigator
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Long term safety | 12 months | Long term safety is assessed by collection of procedure or device related complications. |
| Long term effectiveness (paroxysmal) | 12 months | Freedom from atrial arrhythmias (atrial fibrillation/atrial flutter/atrial tachycardia) recurrence (documented episodes greater than 30 seconds) at 12-month follow-up. |
| Long term effectiveness (persistent) | 12 months | Freedom from symptomatic atrial arrhythmia (atrial fibrillation/atrial flutter/atrial tachycardia) recurrence (documented episodes greater than 30 seconds) at 12-month follow-up |
| Procedural efficiency | Immediately after procedure | Procedure time, ablation time, fluoroscopy time |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Patient-reported Outcome | 12 months | Assessed with 3 items-- How do you feel now compared to pre-ablation: 1) at rest; 2) during mild exercise; and 3) during rigorous exercise |
| Acute safety | 7 days | Assessed by collection of procedure or device related complications that occur within 7 days of the ablation procedure |
| Acute success | Immediately after procedure | Termination of clinical arrhythmia, defined by termination to sinus rhythm or non-inducibility of clinical arrhythmia after ablation (cardioversion allowed prior to inducibility attempt) |
Countries
United States
Outcome results
None listed